The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...

The truth became clear when Regeneron released its Q3FY24 results in October. The company posted lagging net sales for both Eylea and Eylea HD because it had started reporting credit card ...

New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...

Adjusted SG&A expenses increased 9% to $681 million due to higher commercialization-related expenses to support the launch of Eylea HD and higher headcount-related costs. Regeneron recorded ...

Regeneron Pharmaceuticals (NASDAQ ... driven by increased demand for Eylea HD (aflibercept 8 mg), Libtayo (cemiplimab), its key medication in the oncology franchise, as well as revenue growth ...

2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...

Regeneron Pharmaceuticals reported fourth-quarter ... fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the Zacks ...